

# R James White

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7850755/r-james-white-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51  
papers

2,466  
citations

18  
h-index

49  
g-index

58  
ext. papers

3,067  
ext. citations

8.2  
avg, IF

4.43  
L-index

#	Paper	IF	Citations
51	Tadalafil therapy for pulmonary arterial hypertension. <i>Circulation</i> , <b>2009</b> , 119, 2894-903	16.7	769
50	Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 834-44	59.2	618
49	Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. <i>Circulation</i> , <b>2013</b> , 127, 624-33	16.7	238
48	Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. <i>Journal of Heart and Lung Transplantation</i> , <b>2010</b> , 29, 137-49	5.8	141
47	Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2007</b> , 293, L583-90	5.8	99
46	Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension. <i>Liver Transplantation</i> , <b>2009</b> , 15, 30-6	4.5	74
45	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 227-238	35.1	55
44	Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 201, 707-717	10.2	40
43	Transition from parenteral to oral treprostinil in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2017</b> , 36, 193-201	5.8	38
42	Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. <i>Lancet Respiratory Medicine</i> , <b>2016</b> , 4, 894-901	35.1	37
41	Thrombosis, platelets, microparticles and PAH: more than a clot. <i>Drug Discovery Today</i> , <b>2014</b> , 19, 1230-5	8.8	33
40	Customized Internal Reference Controls for Improved Assessment of Circulating MicroRNAs in Disease. <i>PLoS ONE</i> , <b>2015</b> , 10, e0127443	3.7	32
39	Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 204, 209-221	10.2	30
38	Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension. <i>Journal of Cardiovascular Pharmacology</i> , <b>2013</b> , 61, 474-81 <sup>3.1</sup>		27
37	Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics. <i>Pulmonary Circulation</i> , <b>2013</b> , 3, 611-21	2.7	26
36	Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 573-584	35.1	22
35	Recommendations for the use of oral treprostinil in clinical practice: a Delphi consensus project pulmonary circulation. <i>Pulmonary Circulation</i> , <b>2017</b> , 7, 167-174	2.7	20

34	The impact of a pulmonary embolism response team on the efficiency of patient care in the emergency department. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 331-335	5.1	18
33	Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2018</b> , 24, 834-842	1.9	17
32	Thrombin induces fibronectin-specific migration of pulmonary microvascular endothelial cells: requirement of calcium/calmodulin-dependent protein kinase II. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2009</b> , 297, L706-14	5.8	15
31	Chronic therapeutic anticoagulation is associated with decreased thrombotic complications in SARS-CoV-2 infection. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 2640-2645	15.4	13
30	Tissue factor is induced in a rodent model of severe pulmonary hypertension characterized by neointimal lesions typical of human disease. <i>Chest</i> , <b>2005</b> , 128, 612S-613S	5.3	11
29	Novel Analysis of the Oral Treprostinil Combination Therapy Trial Data. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2016</b> , 193, 1434-6	10.2	9
28	A Pharmacokinetic and Tolerability Comparison in Subjects Transitioning From Twice Daily to Three Times Daily Dosing of Oral Treprostinil. <i>Chest</i> , <b>2014</b> , 146, 865A	5.3	9
27	Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension. <i>Respiratory Research</i> , <b>2019</b> , 20, 208	7.3	8
26	Low dose monocrotaline causes a selective pulmonary vascular lesion in male and female pneumonectomized rats. <i>Experimental Lung Research</i> , <b>2018</b> , 44, 51-61	2.3	7
25	Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 2583-93	4	7
24	Estrogen: Friend or Foe in Pulmonary Hypertension?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2016</b> , 193, 1084-6	10.2	7
23	Tumor Necrosis Factor Induces Obliterative Pulmonary Vascular Disease in a Novel Model of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1759-1770	9.5	6
22	Heart Rate Expenditure Correlates with Right Ventricular Function. <i>Annals of the American Thoracic Society</i> , <b>2020</b> , 17, 372-375	4.7	5
21	Clinical and imaging outcomes after intermediate- or high-risk pulmonary embolus. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020952019	2.7	5
20	Liver Backscatter and the Hepatic Vasculature's Autocorrelation Function. <i>Acoustics</i> , <b>2020</b> , 2, 3-12	2	4
19	Direct oral anticoagulant therapy in patients with morbid obesity after intermediate- or high-risk pulmonary emboli. <i>ERJ Open Research</i> , <b>2021</b> , 7,	3.5	4
18	Traversing and labeling interconnected vascular tree structures from 3D medical images <b>2014</b> ,		3
17	Heart rate monitoring improves clinical assessment during 6-min walk. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020972572	2.7	2

16	Pulmonary arterial hypertension: building a better mouse trap for 2010. <i>Drug Discovery Today: Therapeutic Strategies</i> , <b>2004</b> , 1, 351-359		2
15	Update on the Development of Oral Prostacyclin Analogs for the Treatment of PAH. <i>Advances in Pulmonary Hypertension</i> , <b>2009</b> , 8, 32-36	0.5	2
14	Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020973124	2.7	2
13	Aggressive Afterload Lowering to Improve the RV: A New Target for Medical Therapy in PAH?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> ,	10.2	2
12	Combination therapy improves vascular volume in female rats with pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , <b>2019</b> , 317, L445-L455	5.8	1
11	8% Capsaicin Patch as Analgesia for Severe Treprostinil Infusion Site Pain. <i>Pain Medicine</i> , <b>2017</b> , 18, 2515-2517	2.17	1
10	Clinical trial design in phase 2 and 3 trials for pulmonary hypertension. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020941491	2.7	1
9	Reduced Notch1 Cleavage Promotes the Development of Pulmonary Hypertension. <i>Hypertension</i> , <b>2022</b> , 79, 79-92	8.5	0
8	An untapped resource: characteristics of thrombus recovered from intermediate or high risk pulmonary embolus patients. <i>Cardiovascular Pathology</i> , <b>2021</b> , 57, 107392	3.8	0
7	Venous thromboembolism associates with SARS-CoV-2 more than seasonal influenza. <i>Thrombosis Research</i> , <b>2021</b> , 205, 40-43	8.2	0
6	Vasodilator use in precapillary pulmonary hypertension with end stage kidney disease: A single center experience. <i>Respiratory Medicine</i> , <b>2021</b> , 188, 106596	4.6	0
5	Oral treprostinil improves pulmonary vascular compliance in pulmonary arterial hypertension.. <i>Respiratory Medicine</i> , <b>2022</b> , 193, 106744	4.6	
4	Evaluation of Clinical Recovery After Surgical Treatment for Hand Ischemia From Vasospastic and Occlusive Disease Using PROMIS. <i>Hand</i> , <b>2021</b> , 1558944721999727	1.4	
3	EXPRESS: Long term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics. <i>Pulmonary Circulation</i> , <b>2019</b> , 2045894019866335	2.7	
2	Resting heart rate as a surrogate for improvement in intermediate risk pulmonary embolus patients?. <i>Respiratory Medicine</i> , <b>2021</b> , 187, 106578	4.6	
1	Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension.. <i>Respiratory Medicine Case Reports</i> , <b>2022</b> , 37, 101646	1.2	